

AIM

biotech

cancer therapy

patent approval

momentum

pre-market

AIM ImmunoTech (AIM) Explodes 110% Pre-Market After Japan Patent Win Triggers Fresh Catalyst

March 18, 2026 — 9:19 AM EDT · Report #8 · Free Equity Reports Research

SUMMARY

AIM explodes 110% pre-market after securing final Japanese patent approval for Ampligen cancer combination therapy, but dilution risks loom from recent rights offering.

SINCE REPORT -64.7%

DATA BOX

Price	\$1.49
Change	+109.86%
Volume	76.9K
Float	Extremely low
Mkt cap	\$3.00M

Key Data:

- Price: \$1.49 (pre-market)
- Change: +\$0.78 (+109.86%)
- Volume: 76.9K

- Float: Extremely low
- Market Cap: \$3.00M

Report Time: March 18, 2026, 9:18 AM ET

AIM caught fire this morning after announcing final approval of a Japanese patent covering the Company's proprietary use of Ampligen (rintatolimod) in combination with checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) for the treatment of cancer. The stock gapped from \$0.71 to \$1.49 pre-market — a clean 110% pop on news that couldn't be more timely.

Here's why this matters beyond the headline: The patent was granted in September 2025, but had to then pass a 6-month opposition period. That opposition window closed, making the patent official and ironclad. Japan is one of the largest health markets in the world, with Japan and the United States expected to experience the greatest increase in global pancreatic cancer burden by 2030.

The timing couldn't be better. AIM just closed a \$1.8 million rights offering on March 6, giving them fresh capital to work with. More importantly, they're running a Phase 2 trial (DURIPANC) combining Ampligen with AstraZeneca's durvalumab for metastatic pancreatic cancer. Key milestones ahead: enrollment completion planned July 2026; primary endpoint readout in December 2026.

Patent protection runs until December 20, 2039 – further strengthens our intellectual property portfolio in one of the world's largest oncology markets. The claims are broad, covering multiple cancer types, including pancreatic cancer, skin cancer, colorectal cancer, ovarian cancer, melanoma, breast cancer/triple negative breast cancer, head and neck tumors, bladder cancer, renal cell carcinoma, and lung cancer.

But let's talk risk because there's plenty. That \$1,000 per Unit rights offering included one Series G convertible preferred share and 2,000 Class G warrants. Those warrants exercise at \$1.00 — we're already above that level. The rights offering may increase potential dilution because each Unit includes 2,000 warrants.

The company burns through cash consistently. Free cash flow is -\$5.08 million quarterly with net income of -\$17.32 million annually. At a \$3 million market cap, AIM needs constant financing to survive.

What makes this interesting is the setup. Analyst price targets range from \$22.20 to \$23.08 — granted, those are probably stale given the recent rights offering dilution. But that analyst coverage suggests institutional awareness.

Watch \$1.50 as immediate resistance — that's roughly 2x the gap price. Volume needs to hold above 100K to suggest real conviction. If we break back under \$1.20, the gap-fill trade kicks in and you're looking at a potential retrace to \$0.90-\$1.00.

The biotech is chasing the big prize: pancreatic cancer has a brutal 5-year survival rate and represents a massive market opportunity. Patent protection through 2039 gives them runway to monetize any clinical success. But clinical trials are binary events, and AIM hasn't shown profitability or sustainable cash generation.

Position this as a momentum play with defined risk. Rights offering overhang exists, but today's patent news removes a key regulatory uncertainty. Keep stops tight — biotechs can give back gains just as fast as they make them.

This report contains forward-looking statements. Biotech investments carry substantial risk including potential total loss.

This report is for informational purposes only and does not constitute investment advice. Always conduct your own due diligence before making any investment decision.

freeequityreports.com/reports/aim-japan-patent-cancer-therapy-surge-2026-03-18/ · Free Equity Reports Research · March 18, 2026 · Not investment advice.